CN103772176A - Vibsane型二萜衍生物及其药物组合物和应用 - Google Patents
Vibsane型二萜衍生物及其药物组合物和应用 Download PDFInfo
- Publication number
- CN103772176A CN103772176A CN201410065477.8A CN201410065477A CN103772176A CN 103772176 A CN103772176 A CN 103772176A CN 201410065477 A CN201410065477 A CN 201410065477A CN 103772176 A CN103772176 A CN 103772176A
- Authority
- CN
- China
- Prior art keywords
- acid
- alkyl
- vibsane
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 150000004141 diterpene derivatives Chemical class 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 9
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 53
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 33
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 26
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 26
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 20
- -1 aldehyde radical Chemical class 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 210000005036 nerve Anatomy 0.000 claims description 12
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 11
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 11
- 235000015165 citric acid Nutrition 0.000 claims description 11
- 235000019253 formic acid Nutrition 0.000 claims description 11
- 150000007524 organic acids Chemical class 0.000 claims description 11
- 235000006408 oxalic acid Nutrition 0.000 claims description 11
- 229940095064 tartrate Drugs 0.000 claims description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- 229940125782 compound 2 Drugs 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- 229940125904 compound 1 Drugs 0.000 claims description 7
- 229940125898 compound 5 Drugs 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 229930014626 natural product Natural products 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 4
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- GYXPHGPELZUVGI-RYMMUCTNSA-N Vibsanin B Natural products O=C(O[C@H]\1[C@@](O)(C)/C=C/C(=O)/C(/CO)=C/C[C@@](CC/C=C(\C)/C)(C)/C=C/1)/C=C(\C)/C GYXPHGPELZUVGI-RYMMUCTNSA-N 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- GYXPHGPELZUVGI-UHFFFAOYSA-N visbanin B Natural products CC(C)=CCCC1(C)CC=C(CO)C(=O)C=CC(C)(O)C(OC(=O)C=C(C)C)C=C1 GYXPHGPELZUVGI-UHFFFAOYSA-N 0.000 claims description 3
- LSPHULWDVZXLIL-LDWIPMOCSA-N (?)-Camphoric acid Chemical compound CC1(C)[C@@H](C(O)=O)CC[C@@]1(C)C(O)=O LSPHULWDVZXLIL-LDWIPMOCSA-N 0.000 claims description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 2
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 claims description 2
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical class OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 2
- 206010034010 Parkinsonism Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- BLCFCVYGFDLOSC-UHFFFAOYSA-N benzene;benzenesulfonic acid Chemical compound C1=CC=CC=C1.OS(=O)(=O)C1=CC=CC=C1 BLCFCVYGFDLOSC-UHFFFAOYSA-N 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 2
- 230000000955 neuroendocrine Effects 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 230000000269 nucleophilic effect Effects 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 229920003175 pectinic acid Polymers 0.000 claims description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 claims description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims description 2
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- GYXPHGPELZUVGI-QYGPLFBNSA-N vibsanin B Chemical compound CC(C)=CCC[C@@]/1(C)C\C=C(CO)/C(=O)/C=C/[C@@](C)(O)[C@H](OC(=O)C=C(C)C)\C=C\1 GYXPHGPELZUVGI-QYGPLFBNSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 108010025020 Nerve Growth Factor Proteins 0.000 description 16
- 235000002639 sodium chloride Nutrition 0.000 description 16
- 102000015336 Nerve Growth Factor Human genes 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 125000002769 thiazolinyl group Chemical group 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 0 CC(C)(C(CC1)[C@@]2C[C@@]1(C)[C@]1C(C=O)=C(C)*[C@@]11)OC=C2C1=O Chemical compound CC(C)(C(CC1)[C@@]2C[C@@]1(C)[C@]1C(C=O)=C(C)*[C@@]11)OC=C2C1=O 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- MRABDLADFYCOFB-MKCWBWRRSA-N C[C@H](CC=C1CO)[C@H]2C(C=O)=C(C)N[C@@H]2C1=O Chemical compound C[C@H](CC=C1CO)[C@H]2C(C=O)=C(C)N[C@@H]2C1=O MRABDLADFYCOFB-MKCWBWRRSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/757—Unsaturated compounds containing a keto groups being part of a ring containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
- C07C67/29—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
- C07C67/293—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/30—Azulenes; Hydrogenated azulenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
式（I）所示的vibsane型二萜衍生物及其药用盐，其制备方法，以其为有效成分的药物组合物，它们在制备治疗或预防阿兹海默症及其它神经退行性疾病药物中的应用。
Description
技术领域：
本发明属于药物技术领域，具体地，涉及vibsane型二萜衍生物，以其为活性成分的药物组合物，其制备方法，以及它们在制备治疗或预防阿兹海默症及其它神经退行性疾病药物中的应用。
背景技术：
阿兹海默症（Alzheimer’s disease,AD）是继心脑血管疾病及恶性肿瘤后严重威胁人类健康的神经退行性疾病。据统计，2006年，全球AD患者有2千6百万，预计到2050年，将会有近1亿的AD患者，到那时，每85个人中就一名AD患者（Brookmeyer,R.,Johnson,E.,Ziegler-Graham,K.,Arrighi,M.,Alzheimer’s&Dementia,2007,3,186）。而目前市售防治AD的药物中，没有一种可以治愈AD，根据个体差异，部分药物可以达到缓解AD症状与延缓AD恶化的作用，但是这远不能降低AD患者的增长趋势。因此寻找有效的AD药物是一项历史重任。
AD一个重要的病理学特征是大脑中的神经细胞缺失，目前认为较好的治疗思路是防止神经细胞死亡与在退行区域促进生成新的神经细胞。神经增长因子（nerve growth factor,NGF）是一类存在于神经系统中的神经营养因子，它对神经增长起到重要的调节作用，因此类NGF活性或可以促进NGF发挥其作用的小分子可以作为治疗AD的有效药物（Cowan,W,M.,Annu.Rev.Neurosci.2001,24,551）（Tang,W,X.,Kubo,M.,Harada,K.,Hioki,H.,Fukuyama,Y.,Bioorganic &Medicinal Chemistry Letters,2009,19,882）。
天然产物具有结构复杂性和多样性，是大自然经过几千年甚至上万年漫长的进化选择出来的，因此天然产物来源的具有NGF促进活性的化学小分子可能表现出更为出色的药理活性。
基于此，本发明设计以骨架独特而自然界中含量较大的vibsaninB二萜为模板，通过简单的重排反应（Fukuyama,Y.;Minami,H.;Takaoka,S.;Kodama,M.;Kawazu,K.;Nemoto,H.,Tetrahedron Letters,1997,38,1435）合成具有新颖骨架类型的二萜化合物，以发现具有NGF促进活性的化合物，并充分利用植物资源。
发明内容：
本发明的目的在于：提供一类新的vibsane型二萜衍生物，以其为活性成分的药物组合物，其制备方法，以及vibsane型二萜衍生物及其药物组合物在制备预防或治疗阿兹海默症及其它神经退行性疾病的药物中的应用。
本发明的上述目的是通过如下的技术方案得以实现的：
式（I）所示的vibsane型二萜衍生物或其药用盐，
式中小写字母a、b代表独立的双键或单键，用表示；Y为O或N原子；
其中a为双键时，R2不存在，R1选自醛基、羧基、羟甲基、亚甲基卤素（-CH2X）、C1-10烷氧基、C1-10酯基、-CH2NH2/-CH2NR2，其中R为H和C1-10烷基或都为C1-10烷基；a为单键时，R2为H，R1选自醛基、羧基、羟甲基、亚甲基卤素（-CH2X）、C1-10烷氧基、C1-10酯基、-CH2NH2/-CH2NR2，其中R为H和C1-10烷基或都为C1-10烷基；R2可以是任意具亲核性基团（如，丙二酸酯、丙酮等），R1为亚甲基（CH2）；
b为双键时，R5和R6选自H；b为单键时，R5选自=O、-OH、卤素、C1-10烷氧基、C1-10酯基、-NH2/-NR2，其中R为H和C1-10烷基或都为C1-10烷基；R6选自-OH、卤素、C1-10烷氧基、C1-10酯基；
R3选自羟基、醛基、甲酸的C1-10酯基、羟甲基、亚甲基卤素（-CH2X）、烯丙基、异戊烯基、C1-10烷氧基、C1-10酯基、-CH2NH2/-CH2NR2，其中R为H和C1-10烷基或都为C1-10烷基；
R4选自羟基、醛基、卤素（F、Cl、Br）、C1-10烷氧基、C1-10酯基、-NH2/-NR2，其中R为H和C1-10烷基或都为C1-10烷基；
如式（I）所示的vibsane型二萜衍生物，为如下式（II）和式（III）所示的vibsane型二萜衍生物，
其中R1、R2相同或不同，分别选自羟基、醛基、卤素（F、Cl、Br）、C1-10烷氧基、C1-10酯基、-NH2/-NR2，其中R为H和C1-10烷基或都为C1-10烷基；
如上所示的vibsane型二萜衍生物，为如下化合物：
如上所示的vibsane型二萜衍生物的制备方法，包括下述步骤：
将天然产物vibsanin B在甲苯中加热回流，得化合物1，然后将化合物1用碱处理转化为化合物2，其通过还原、TES保护得到化合物5，化合物5经酯化及去保护化得到化合物6；化合物2经氧化得到化合物4，
本发明还提供用于治疗或预防阿兹海默症及其它神经退行性疾病的药物组合物，其中含有治疗有效量的上述的vibsane型二萜衍生物或其药用盐和药学上可接受的载体。
药物组合物，其中含有治疗有效量的vibsane型二萜衍生物或其药用盐和药学上可接受的载体。
如所述的所示的vibsane型二萜衍生物或其药用盐，其中所述的药用盐是指药学上可接受的盐，是与有机酸形成的盐，所述的有机酸为酒石酸、柠檬酸、甲酸、乙酸、乙二酸、丁酸、草酸、马来酸、琥珀酸、己二酸、藻酸、柠檬酸、天冬氨酸、苯苯磺酸、樟脑酸、樟脑磺酸、二葡糖酸、环戊烷丙酸、十二烷基硫酸、乙磺酸、葡庚糖酸、甘油磷酸、半硫酸、庚酸、己酸、延胡索酸、2-羟基乙磺酸、乳酸、马来酸、甲磺酸、烟酸、2-萘磺酸、扑酸、果胶酯酸、3-苯基丙酸、苦味酸、新戊酸、丙酸、琥珀酸、酒石酸、硫代氰酸、对-甲苯磺酸盐和十一烷酸盐。
本发明同时还提供了上面所示的vibsane型二萜衍生物或其药用盐在制备治疗或预防阿兹海默症及其它神经退行性疾病的药物中的应用。
如所述的应用，其中所述的其它神经退行性疾病为帕金森综合症、2型糖尿病、血脂代谢障碍、高血压及心血管并发症、精神性疾病、认知障碍、神经退行性病变、神经内分泌失调。
除非另有说明，本发明使用的术语“烷基”是指直链或者支链的饱和一价烃基，其中烷基可以任选地被一个或多个取代基取代。术语“烷基”也包括直链和支链烷基，除非另作说明。在某些实施方式中，烷基是具有1到20（C1-20）、1到15（C1-15）、1到12（C1-12）、1到10（C1-10）、或者1到6（C1-6）个碳原子的直链饱和的一价烃基，或者具有3到20（C3-20）、3到15（C3-15）、3到12（C3-12）、3到10（C3-10）、或者3到6（C3-6）个碳原子的支链的饱和一价烃基。本发明使用的直链C1-6和支链C3-6烷基也被称为“低级烷基”。烷基的实施方式包括但不限于甲基、乙基、丙基（包括所有同分异构形式）、n-丙基、异丙基、丁基（包括所有同分异构形式）、n-丁基、异丁基、t-丁基、戊基（包括所有同分异构形式）、和己基（包括所有同分异构形式）。例如，C1-6烷基指具有1到6个碳原子的直链饱和一价烃基或者具有3到6个碳原子的支链饱和一价烃基。
除非另作说明，本发明使用的术语“烯基”是指包含一个或多个碳碳双键（在一个实施方式中1至5个）的直链或者支链一价烃基。烯基可以任选地被一个或多个取代基取代。术语“烯基”也包括“顺式（cis）”和“反式（trans）”结构的基团，或者本领域普通技术人员所理解的“E”和“Z”式结构。除非另作说明，本发明使用的术语“烯基”包括直链和支链烯基。例如，C2-6烯基是指2到6个碳原子的直链不饱和一价烃基或者3到6个碳原子的支链不饱和一价烃基。在某些实施方式中，烯基是2到20（C2-20）、2到15（C2-15）、2到12（C2-12）、2到10（C2-10）、或者2到6（C2-6）个碳原子的直链一价烃基，或者3到20（C3-20）、3到15（C3-15）、3到12（C3-12）、3到10（C3-10）、或者3到6（C3-6）个碳原子的支链一价烃基。烯基的实施方式包括但不限于乙烯基、丙烯-1-基、丙烯-2-基、烯丙基、丁烯基、以及4-甲基丁烯基。
除非另作说明，本发明使用的术语“炔基”是指包含一个或多个碳碳三键（在一个实施方式中1到5个）的直链或者支链一价烃基。炔基可以任选地被一个或多个取代基取代。除非另作说明，术语“炔基”也包括直链和支链炔基。在某些实施方式中，炔基是2到20（C2-20）、2到15（C2-15）、2到12（C2-12）、2到10（C2-10）、或者2到6（C2-6）个碳原子的直链一价烃基，或者3到20（C3-20）、3到15（C3-15）、3到12（C3-12）、3到10（C3-10）、或者3到6（C3-6）个碳原子的支链的一价烃基。炔基的实施方式包括但不限于乙炔基（-C≡CH）和炔丙基（-CH2C≡CH）。例如，C2-6炔基指2到6个碳原子的直链不饱和一价烃基或者3到6个碳原子的支链不饱和一价烃基。
除非另作说明，本发明使用的术语“环烷基”是指环状饱和桥和/或非桥的一价烃基，其可以任选地被一个或多个本发明所述的取代基取代。在某些实施方式中，环烷基具有从3到20（C3-20）、从3到15（C3-15）、从3到12（C3-12）、从3到10（C3-10）、或者从3到7（C3-7）个碳原子。环烷烃基的实施方式包括但不限于环丙基、环丁基、环戊基、环己基、环庚基、十氢萘基和金刚烷基。
除非另作说明，本发明使用的术语“杂烷基”、“杂烯基”和“杂炔基”分别是指一个或多个碳原子被杂原子替换的烷基、链烯基和炔基。
除非另作说明，本发明使用的术语“杂原子”是指除了碳或者氢以外的其他任何原子。在某些实施方式中，术语“杂原子”是指N、O、S、Si或P。在其他实施方式中，术语“杂原子”是指N、O或者S。
除非另作说明，本发明使用的术语“芳基”是指单环芳基和/或包含至少一个芳香烃环的多环单价芳基。在某些实施方式中，芳基具有从6到20（C6-20）、从6到15（C6-15）、或者从6到10（C6-10）个环原子。芳基的实施方式包括但不限于苯基、萘基、芴基、薁基（azulenyl）、蒽基、菲基、芘基、联苯基和三联苯基。芳基也指其中一个环是芳香族的和其他环可以是饱和的，部分不饱和的或者芳香族的二环或者三环的碳环，例如二氢萘基、茚基、二氢茚基或者四氢萘基（萘满基（tetralinyl））。在某些实施方式中，芳基也可以任选地被一个或多个取代基取代。
除非另作说明，本发明使用的术语“芳基烷基”或者“芳烷基”是指用芳基取代的单价烷基。在某些实施方式中，烷基和芳基可任选地被一个或多个取代基取代。
本发明的化合物vibsane型二萜衍生物或其盐可经口或不经过口给药，给药量因药物不同而各有不同，对成人来说，每天1-1000mg比较合适。
附图说明：
图1为本发明的化合物vibsane型二萜衍生物NGF的促进活性结果图。
具体实施方式：
下面的试验实施例、实施例和制剂实施例可更详细地说明本发明，但不以任何形式限制本发明。
实施例1：
本发明的化合物vibsane型二萜衍生物具有明显的NGF促进活性，实验方法和结果如下：
一、实验方法：
1.PC12采用Ham's F12K+12.5%HS+2.5%FBS+100U/mL双抗的培养基进行培养，培养箱温度37℃，5%CO2；
2.当PC12细胞长至合适数量时，取PC12细胞，胰酶消化，制成细胞悬液；
3.将细胞悬液吸至15mL离心管中，1500rpm，3min；
4.离心结束后，离心管用酒精消毒后拿进超净台，将上清倒入废液缸；
5.加入新的完全培养基5mL，用移液器吹打十次，尽量吹散细胞，但不能太用力；
6.取0.2ml细胞悬液，加入到细胞计数管中，再加0.8ml PBS，混匀，计数；
7.将细胞浓度调整至5×104cells/ml，加入预先用PLL包被好的48孔板，每孔0.2mL，放入细胞培养箱培养；
8.第二天，将原培养基吸出，然后加入含Ham's F12K+2.5%FBS的培养基（48孔，0.24mL/孔），加入5ng/mL的NGF及待测化合物；
9.实验设计：各组设计各做3个重复
Blank对照：不加NGF，只有细胞和终浓度为0.01%的DMSO；
阴性对照组：含NGF终浓度为5ng/mL和终浓度为0.01%的DMSO；
阳性对照组：含NGF终浓度为50ng/mL和终浓度为0.01%的DMSO；
化合物组：化合物终浓度10μM（含DMSO，DMSO终浓度为0.01%），同时加入终浓度为5ng/mL的NGF诱导72h。
10.细胞放入细胞培养箱中继续培养；
11.每天观察细胞分化情况，在加入化合物72h后统计细胞分化比例，统计方法：
（1）判断标准：突起长度大于细胞直径的细胞，认为是有分化的细胞；
（2）和阴性对照相比，如果化合物组突起长度和数量无明显提高，认为无明显分化活性，不统计分化率。
（3）如果化合物组突起的数量、长度明显比阴性对照多，认为该化合物有分化活性，要求对分化的细胞数量作出统计，每组统计不少于5个视野；
二、结果：（见图1）。本发明对一系列vibsane型二萜衍生物进行了体外NGF促进PC12细胞分化活性评价，结果显示该类化合物对PC12细胞分化具有较明显地分化活性。
实施例2：
化合物1的制备：
将2gvibsanin B溶于50mL甲苯，氩气保护下加热回流反应36h，加入4g200～300目硅胶搅拌均匀，减压蒸除溶剂，剩余物经硅胶柱层析（石油醚：乙酸乙酯=4：1）得到化合物1（产率88%）。1H NMR(400MHz,CDCl3)δ6.98(d,J=12.3Hz,1H),6.56(t,J=7.1Hz,1H),5.67–5.68(m,1H),5.16(t,J=12.3Hz,1H),5.01(ddd,J=7.0,5.8,1.3Hz,1H),4.25(s,2H),3.02(ddd,J=9.6,7.2,4.5Hz,1H),2.93(dd,J=17.6,7.2Hz,1H),2.64(dd,J=17.7,4.5Hz,1H),2.55(br,1H),2.33(d,J=7.1Hz,2H),2.20(d,J=1.0Hz,3H),2.15(s,3H),1.94(d,J=1.0Hz,3H),1.79–1.90(m,2H),1.65(s,3H),1.57(s,3H),1.21(ddd,J=10.2,6.8,3.5Hz,2H),0.90(s,3H).13C NMR(100MHz,CDCl3)δ208.01,205.86,163.29,160.59,142.18,139.10,137.51,131.88,124.30,114.79,112.60,64.31,48.32,46.10,44.23,40.18,39.99,30.29,27.85,25.85,23.98,20.76,17.82.HRMS(EI)calcd for C25H36O5[M]+:416.2563,found416.2558.
实施例3：
化合物2的制备：
将200mg化合物1溶于2.4mL甲醇，0℃下缓慢滴加10eq2NNaOH的甲醇溶液，滴完后室温下搅拌30min，加入0.6mL饱和NH4Cl溶液猝灭反应，乙酸乙酯萃取，有机相用饱和食盐水洗3次，无水NaSO4干燥，减压蒸除溶剂，得到淡黄色油状物，经硅胶柱层析（石油醚：乙酸乙酯=4：1）得到化合物2（产率60%）。1H NMR(400MHz,CDCl3)δ10.00(s,1H),6.82(dd,J=9.7,5.2Hz,1H),5.12–5.18(m,1H),4.27(dd,J=40.1,12.8Hz,2H),3.03–3.17(m,2H),2.95–3.02(m,1H),2.46–2.59(m,4H),2.22(dd,J=14.9,4.9Hz,1H),2.16(d,J=1.3Hz,3H),1.85–2.11(m,5H),1.69(s,3H),1.63(s,3H),1.54–1.62(m,2H),0.80(s,3H).13C NMR(100MHz,CDCl3)δ202.28,189.16,163.24,143.81,141.25,137.00,131.42,124.57,64.28,54.65,51.36,41.06,40.24,39.55,38.06,25.70,23.96,22.89,17.67,15.24;HRMS(EI)calcd for C20H28O3[M]+:316.2038,found316.2046。
实施例4：
化合物4的制备：
将1g化合物2溶于30mL二氯甲烷与二甲亚砜的混合溶剂（5:1），加入2.2g IBX，加后室温下搅拌8h，将反应液用硅藻土过滤，减压蒸除溶剂，得到黄色油状物，该油状物经硅胶柱层析（石油醚：乙酸乙酯=10：1）得到化合物4为白色固体，该固体在石油醚/乙酸乙酯中重结晶可得到无色块状晶体（产率82%）。MP:150–152℃;1H NMR(400MHz,CDCl3)δ9.99(s,1H),6.87(d,J=2.3Hz,1H),3.37(dd,J=11.0,1.5Hz,1H),3.24(dd,J=20.3,9.6Hz,1H),2.80(br,1H),2.58–2.77(m,3H),2.26(dt,J=14.6,3.7Hz,1H),2.12(s,3H),1.49–1.70(m,4H),1.42(dt,J=12.0,4.5Hz,1H),1.36(dd,J=14.6,3.2Hz,1H),1.30(s,3H),1.26(s,3H),1.25–1.19(m,1H),0.76(s,3H).13C NMR(100MHz,CDCl3)δ204.88,189.62,163.01,148.93,138.77,117.32,79.26,51.62,49.54,42.21,40.70,39.48,37.68,34.13,28.91,28.00,25.73,25.61,19.20,15.19;HRMS(EI)calcd for C20H26O3[M]+:314.1882,found314.1888。
实施例5：
化合物5的制备：
将1mmol化合物2溶于10ml二氯甲烷，加入3mmol三乙胺，搅拌均匀后加入2mmol的三乙基氯硅烷，室温下搅拌6h，减压蒸除溶剂，得到淡黄色油状物。将该黄色油状物溶于12mL二氯甲烷与异丙醇的混合溶剂（3:1），置于0℃搅拌10min，分三次加入1mmolNaBH4，加完后在室温下反应24h。0℃下向上述体系加入1ml饱和NH4Cl溶液猝灭反应接着加入50ml乙酸乙酯搅拌分层，有机相用饱和NaCl溶液洗涤3次，无水Na2SO4干燥，减压蒸除溶剂，得到黄色油状物，该油状物经硅胶柱层析（石油醚：乙酸乙酯=20：1）得到化合物5为黄色油状物（产率95%）。1H NMR(600MHz,CDCl3)δ6.83(m,1H),5.12(ddd,J=7.1,5.8,1.3Hz,1H),4.47(dt,J=15.3,2.2Hz,1H),4.35(d,J=10.4Hz,1H),4.25(m,1H),4.10(dd,J=11.5,5.4Hz,1H),2.93(overlap,3H),2.51(dd,J=14.7,9.9Hz,1H),2.38(m,1H),2.18(m,1H),2.10(m,1H),1.95(m,1H),1.74(s,3H),1.68(s,3H),1.63(s,3H),1.61(s,3H),1.60–1.52(m,2H),1.04(br,1H),0.95(t,J=8.0Hz,9H),0.89(s,3H),0.63(q,J=8.0Hz,6H).13C NMR(150MHz,CDCl3)δ202.99,141.14,139.64,139.06,132.93,131.65,124.83,61.24,58.37,54.75,51.52,41.32,40.15,39.85,36.55,25.94,24.16,22.63,17.81,14.50,7.03,4.58.HRMS(EI)calcd for C26H44O3Si[M]+:432.3060,found432.3065。
实施例6：
化合物3的制备：
将0.1mmol化合物5溶于1mL二氯甲烷，0℃下加入0.12mmol3,3-二甲基丙酸与0.05mmol4-二甲胺基吡啶，搅拌10min，加入0.2mmol二环己基碳二酰亚胺，室温搅拌过夜。加入5mL水与5mL乙酸乙酯搅拌分层，有机相用饱和NaCl溶液洗涤3次，无水Na2SO4干燥，减压蒸除溶剂，得到黄色油状物。将该黄色油状物溶于1ml四氢呋喃与水的混合溶剂（8:2），加入0.5mL冰乙酸，室温搅拌8h，乙酸乙酯萃取，有机相用饱和NaCl溶液洗涤3次，无水Na2SO4干燥，减压蒸除溶剂，得到黄色油状物。经硅胶柱层析（石油醚：乙酸乙酯=10：1）得到化合物3为黄色油状物（产率88%）。1H NMR(600MHz,CDCl3)δ6.73(dd,J=9.6,5.2Hz,1H),5.60–5.66(m,1H),5.01(t,J=6.9Hz,1H),4.77(t,J=9.3Hz,1H),4.53(t,J=10.5Hz,1H),4.19–4.34(m,2H),2.98(ddd,J=20.4,12.0,5.3Hz,2H),2.90(dd,J=24.1,7.8Hz,1H),2.39–2.49(m,2H),2.21(dd,J=14.7,5.0Hz,1H),2.16(d,J=1.0Hz,3H),2.01(dt,J=18.9,6.2Hz,1H),1.89–1.94(m,1H),1.88(t,J=4.5Hz,3H),1.75–1.78(m,4H),1.68(t,J=6.5Hz,2H),1.65(s,3H),1.61(d,J=1.3Hz,1H),1.59(s,3H),1.40–1.50(m,2H),0.91(s,3H).13C NMR(150MHz,CDCl3)δ204.56,166.70,157.45,142.81,142.15,141.33,131.75,128.26,124.48,115.81,64.95,59.30,54.70,51.70,41.23,40.36,40.14,36.50,27.62,25.87,24.16,22.85,20.39,17.91,14.72.HRMS(EI)calcd for C25H36O4[M]+:400.2614,found400.2621。
制剂实施例1：
按实施例2-6的方法先制得本发明的上述化合物，以及利用有机酸（酒石酸，柠檬酸，甲酸，乙二酸等）或无机酸（盐酸，硫酸，磷酸等）制成的盐，按常规加注射用水，精滤，灌封灭菌制成注射液。
制剂实施例2：
按实施例2-6的方法先制得本发明的上述化合物，以及利用有机酸（酒石酸，柠檬酸，甲酸，乙二酸等）或无机酸（盐酸，硫酸，磷酸等）制成的盐,将其溶于无菌注射用水中，搅拌使溶，用无菌抽滤漏斗过滤，再无菌精滤，分装于2安瓿中，低温冷冻干燥后无菌熔封得粉针剂。
制剂实施例3：
按实施例2-6的方法先制得本发明的上述化合物，以及利用有机酸（酒石酸，柠檬酸，甲酸，乙二酸等）或无机酸（盐酸，硫酸，磷酸等）制成的盐，与赋形剂重量比为9:1的比例加入赋形剂，制成粉剂。
制剂实施例4：
按实施例2-6的方法先制得本发明的上述化合物，以及利用有机酸（酒石酸，柠檬酸，甲酸，乙二酸等）或无机酸（盐酸，硫酸，磷酸等）制成的盐，按其与赋形剂重量比为1:5-1:10的比例加入赋形剂，制粒压片。
制剂实施例5：
按实施例2-6的方法先制得本发明的上述化合物，以及利用有机酸（酒石酸，柠檬酸，甲酸，乙二酸等）或无机酸（盐酸，硫酸，磷酸等）制成的盐，按常规口服液制法制成口服液。
制剂实施例6：
按实施例2-6的方法先制得本发明的上述化合物，以及利用有机酸（酒石酸，柠檬酸，甲酸，乙二酸等）或无机酸（盐酸，硫酸，磷酸等）制成的盐，按其与赋形剂重量比为5:1的比例加入赋形剂，制成胶囊或颗粒剂或冲剂。
制剂实施例7：
按实施例2-6的方法先制得本发明的上述化合物，以及利用有机酸（酒石酸，柠檬酸，甲酸，乙二酸等）或无机酸（盐酸，硫酸，磷酸等）制成的盐，按其与赋形剂重量比为3:1的比例加入赋形剂，制成胶囊或颗粒剂或冲剂。
Claims (10)
1.式（I）所示的vibsane型二萜衍生物或其药用盐，
式中小写字母a、b代表独立的双键或单键，用
表示；Y为O或N原子；
其中a为双键时，R2不存在，R1选自醛基、羧基、羟甲基、亚甲基卤素（-CH2X）、C1-10烷氧基、C1-10酯基、-CH2NH2/-CH2NR2，其中R为H和C1-10烷基或都为C1-10烷基；a为单键时，R2为H，R1选自醛基、羧基、羟甲基、亚甲基卤素（-CH2X）、C1-10烷氧基、C1-10酯基、-CH2NH2/-CH2NR2，其中R为H和C1-10烷基或都为C1-10烷基；R2可以是任意具亲核性基团（如，丙二酸酯、丙酮等），R1为亚甲基（CH2）；
b为双键时，R5和R6选自H；b为单键时，R5选自=O、-OH、卤素、C1-10烷氧基、C1-10酯基、-NH2/-NR2，其中R为H和C1-10烷基或都为C1-10烷基；R6选自-OH、卤素、C1-10烷氧基、C1-10酯基；
R3选自羟基、醛基、甲酸的C1-10酯基、羟甲基、亚甲基卤素（-CH2X）、烯丙基、异戊烯基、C1-10烷氧基、C1-10酯基、-CH2NH2/-CH2NR2，其中R为H和C1-10烷基或都为C1-10烷基；
R4选自羟基、醛基、卤素（F、Cl、Br）、C1-10烷氧基、C1-10酯基、-NH2/-NR2，其中R为H和C1-10烷基或都为C1-10烷基。
2.如权利要求1式（I）所示的vibsane型二萜衍生物，为如下式（II）和式（III）所示的vibsane型二萜衍生物，
其中R1、R2相同或不同，分别选自羟基、醛基、卤素（F、Cl、Br）、C1-10烷氧基、C1-10酯基、-NH2/-NR2，其中R为H和C1-10烷基或都为C1-10烷基。
3.如权利要求1或2所示的vibsane型二萜衍生物，为如下化合物：
4.权利要求1或2或3所示的vibsane型二萜衍生物的制备方法，包括下述步骤：
将天然产物vibsanin B在甲苯中加热回流，得化合物1，然后将 化合物1用碱处理转化为化合物2，其通过还原、TES保护得到化合物5，化合物5经酯化及去保护化得到化合物6；化合物2经氧化得到化合物4，
5.用于治疗或预防阿兹海默症及其它神经退行性疾病的药物组合物，其中含有治疗有效量的权利要求1或2或3所示的vibsane型二萜衍生物或其药用盐和药学上可接受的载体。
6.药物组合物，其中含有治疗有效量的权利要求1或2或3所示的vibsane型二萜衍生物或其药用盐和药学上可接受的载体。
7.如权利要求1所述的所示的vibsane型二萜衍生物或其药用盐，其特征在于所述的药用盐是指药学上可接受的盐，是与有机酸形成的盐，所述的有机酸为酒石酸、柠檬酸、甲酸、乙酸、乙二酸、丁酸、草酸、马来酸、琥珀酸、己二酸、藻酸、柠檬酸、天冬氨酸、苯苯磺酸、樟脑酸、樟脑磺酸、二葡糖酸、环戊烷丙酸、十二烷基硫酸、乙磺酸、葡庚糖酸、甘油磷酸、半硫酸、庚酸、己酸、延胡索酸、2-羟基乙磺酸、乳酸、马来酸、甲磺酸、烟酸、2-萘磺酸、扑酸、果胶酯酸、3-苯基丙酸、苦味酸、新戊酸、丙酸、琥珀酸、酒石酸、硫代氰酸、对-甲苯磺酸盐和十一烷酸盐。
8.权利要求1或2或3所示的vibsane型二萜衍生物或其药用盐 在制备治疗或预防阿兹海默症的药物中的应用。
9.权利要求1或2或3所示的vibsane型二萜衍生物或其药用盐在制备治疗或预防其它神经退行性疾病的药物中的应用。
10.如权利要求9所述的应用，其中所述的其它神经退行性疾病为帕金森综合症、2型糖尿病、血脂代谢障碍、高血压及心血管并发症、精神性疾病、认知障碍、神经退行性病变、神经内分泌失调。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410065477.8A CN103772176B (zh) | 2014-02-26 | 2014-02-26 | Vibsane型二萜衍生物及其药物组合物和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410065477.8A CN103772176B (zh) | 2014-02-26 | 2014-02-26 | Vibsane型二萜衍生物及其药物组合物和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103772176A true CN103772176A (zh) | 2014-05-07 |
| CN103772176B CN103772176B (zh) | 2016-05-11 |
Family
ID=50565006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410065477.8A Active CN103772176B (zh) | 2014-02-26 | 2014-02-26 | Vibsane型二萜衍生物及其药物组合物和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103772176B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105237415A (zh) * | 2015-05-18 | 2016-01-13 | 中国科学院昆明植物研究所 | Vibsanin B衍生物及其药物组合物和其在制药中的应用 |
| CN115073355A (zh) * | 2022-07-13 | 2022-09-20 | 中国科学院昆明植物研究所 | 环庚烯并氮氧杂二萜衍生物及其药物组合物和其在制药中的应用 |
| CN116063315A (zh) * | 2021-11-03 | 2023-05-05 | 沈阳药科大学 | 珊瑚树中具有八元环新骨架的vibsane型二萜类化合物或其盐及其制备方法和应用 |
-
2014
- 2014-02-26 CN CN201410065477.8A patent/CN103772176B/zh active Active
Non-Patent Citations (4)
| Title |
|---|
| MIWA KUBO ET AL.: "Aldovibsanins, Enol Ester Free Vibsane-Type Diterpenes from Viburnum", 《CHEM. PHARM. BULL.》, vol. 47, no. 2, 28 February 1999 (1999-02-28), pages 295 - 296 * |
| XIU GAO ET AL.: "Vibsatins A and B, Two New Tetranorvibsane-Type Diterpenoids from Viburnum tinus cv. variegatus", 《ORG. LETT.》, vol. 16, 22 January 2014 (2014-01-22), pages 980 - 983 * |
| XUAN-QIN CHEN ET AL.: "Triterpenoids and Diterpenoids from Viburnum chingii", 《CHEM. PHARM. BULL.》, vol. 59, no. 4, 27 January 2011 (2011-01-27), pages 496 - 498 * |
| YOSHIYASU FUKUYAMA ET AL.: "Absolute Structure of Vibsanins B and C, and Their Chemical Correlation", 《TETRAHEDRON LETTERS》, vol. 38, no. 8, 31 December 1997 (1997-12-31), pages 1435 - 1438, XP004053080, DOI: doi:10.1016/S0040-4039(97)00041-5 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105237415A (zh) * | 2015-05-18 | 2016-01-13 | 中国科学院昆明植物研究所 | Vibsanin B衍生物及其药物组合物和其在制药中的应用 |
| CN116063315A (zh) * | 2021-11-03 | 2023-05-05 | 沈阳药科大学 | 珊瑚树中具有八元环新骨架的vibsane型二萜类化合物或其盐及其制备方法和应用 |
| CN116063315B (zh) * | 2021-11-03 | 2024-04-26 | 沈阳药科大学 | 珊瑚树中具有八元环骨架的vibsane型二萜类化合物或其盐及其制备方法和应用 |
| CN115073355A (zh) * | 2022-07-13 | 2022-09-20 | 中国科学院昆明植物研究所 | 环庚烯并氮氧杂二萜衍生物及其药物组合物和其在制药中的应用 |
| CN115073355B (zh) * | 2022-07-13 | 2023-11-10 | 中国科学院昆明植物研究所 | 环庚烯并氮氧杂二萜衍生物及其药物组合物和其在制药中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103772176B (zh) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI648257B (zh) | 牛樟芝化合物、製備方法及其用途 | |
| CN113666824B (zh) | 一种大麻二酚-2-丙酸酯及其应用 | |
| CN103772176A (zh) | Vibsane型二萜衍生物及其药物组合物和应用 | |
| WO2010062372A2 (en) | Methods for modulating nf-kb using gibberellins | |
| CN103709223A (zh) | 达玛烷三萜衍生物及其药物组合物和其在制药中的应用 | |
| CN107540658A (zh) | 一种具抗肿瘤活性的高乌甲素氮杂肉桂酸杂合体及其合成方法 | |
| EP2213679A1 (en) | Water-soluble triterpenephenol compounds having antitumor activity and the preparation thereof | |
| CN105646394B (zh) | 蒎烷基噻唑衍生物及其合成方法和应用 | |
| CN103044250B (zh) | 羧酸衍生物类化合物及其制备方法和应用 | |
| CN100522959C (zh) | 一类6-芳基-3-环氨基甲基吡喃酮类衍生物的制备及用途 | |
| CN115636809B (zh) | 一种查尔酮类衍生物的合成及其制药应用 | |
| CN110092769B (zh) | 一种色烯衍生物及其合成方法和应用 | |
| CN104230915B (zh) | 含噻唑烷二酮的苯基哌嗪衍生物及其制备方法与用途 | |
| CN114478502B (zh) | 香豆素类化合物及其合成方法 | |
| CN103864765B (zh) | 含有五元杂环的苯并氮杂卓类衍生物、其制备方法和用途 | |
| CN101974016A (zh) | 酰胺类化合物及其制备方法和用途 | |
| CN105982885A (zh) | 一种补骨脂黄酮甲醚及其类似物的用途 | |
| CN104774171A (zh) | 3-氨基-3-羟甲基氧化吲哚、3-羟基-3-羟甲基氧化吲哚衍生物及其制备方法和应用 | |
| CN103087009A (zh) | 羧酸衍生物类化合物及其制备方法和应用 | |
| CN104003998B (zh) | 冬凌草甲素14-o-取代氮芥衍生物、制备方法及用途 | |
| CN105367421A (zh) | 荚蒾乙素、其制备方法及用途 | |
| CN105985244A (zh) | 化合物、其分离方法、合成方法及用途 | |
| CN114874135B (zh) | 一类抗乳腺癌的小分子化合物及其制备方法 | |
| CN103880793B (zh) | 含呋喃亚胺类化合物及其制备方法和用途 | |
| CN103724321A (zh) | 一氧化氮和硫化氢供体型苯酞衍生物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |